Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 104

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 104
---
 of grant based on the fair value of our common shares on that same date.Share-Based Compensation Share-based compensation expense for all awards was allocated as follows: 

        Year Ended December 31,

        2024

        2023

        (in thousands)

        Research and development
         
        $
        13,378

        $
        13,239

        General and administrative

        9,782

        11,824

        Total share-based compensation expense
         
        $
        23,160

        $
        25,063

      Share-based compensation expense by type of award was as follows:

        Year Ended December 31,

        2024

        2023

        (in thousands)

        Stock options
         
        $
        20,056

        $
        22,422

        Restricted share units

        2,871

        2,298

        ESPP

        233

        343

        Total share-based compensation expense
         
        $
        23,160

        $
        25,063

      As of December 31, 2024, there was $19.9 million and $4.5 million of unrecognized share-based compensation expense to be recognized over a weighted-average remaining vesting period of 1.0 years and 1.6 years related to unvested stock options and unvested restricted share units, respectively. 

13. Employee Savings PlanThe Company offers its employees in the United States the ability to participate in a 401(k) savings plan and offers its employees in Canada the ability to participate in a registered retirement savings plan. The Company makes non-matching employer contributions into both of these plans on behalf of participants equal to 3% of their base salary. The Company has recorded an expense of $0.8 million and $0.9 million in matching contributions for the years ended December 31, 2024 and 2023.

14. Collaboration ArrangementsDebiopharm Clinical Study and Collaboration Agreement

123

In January 2024, the Company entered into a clinical study and collaboration agreement with Debiopharm International S.A. (“Debiopharm”), a privately-owned, Swiss-based biopharmaceutical company, with the aim to explore the synergy between the Company’s compound, lunresertib, and Debiopharm’s compound, Debio 0123, a WEE1 inhibitor (the “Debio Collaboration